ReviewNature reviews. Cardiology2018
Interventions for lower extremity peripheral artery disease.
Review in Nature reviews. Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Liquid Drug Delivery Approaches for the Treatment of Occlusive Arterial Disease: A Systematic Review.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2024Pooled it
- Accuracy of multimodal intravascular imaging in evaluating neointimal tissue in a swine femoropopliteal artery stent model.Cardiovascular intervention and therapeutics · 2026Article
- Histology-validated comparison of angioscopy, IVUS, and OFDI for assessing stent strut coverage in femoropopliteal arteries with thin neointima.Cardiovascular intervention and therapeutics · 2026Article
- Clinical Efficacy of Periosteum-Preserving Iliac Crest Transverse Transport for Symptomatic High-Level Lower Extremity Arteriosclerosis Obliterans.Chronic diseases and translational medicine · 2026Article
- Revascularization Enhances Walking Dynamics in Patients with Peripheral Artery Disease.Applied mechanics (Basel, Switzerland) · 2025Article
- FPR2 Agonism Attenuates Restenosis by Mitigating Neointimal Hyperplasia via ELOVL6.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Autologous platelet rich gel in treatment of lower limb atherosclerotic occlusive disease in diabetic patients.World journal of diabetes · 2025Article
- Biomaterial-based vascularization strategies for enhanced treatment of peripheral arterial disease.Journal of nanobiotechnology · 2025Review
- The best devices for superficial femoral artery, with "limited" cases and vessel preparations.Cardiovascular diagnosis and therapy · 2024Article
- Maglev-fabricated long and biodegradable stent for interventional treatment of peripheral vessels.Nature communications · 2024Article
- Generation of Autologous Vascular Endothelial Cells for Patients with Peripheral Artery Disease.Journal of cardiovascular translational research · 2024Article
- Macrophage scavenger receptor A1 promotes skeletal muscle regeneration after hindlimb ischemia.Journal of biomedical research · 2024Article
- Comparing Endovascular Approaches in Lower Extremity Artery Disease: Insights from a Network Meta-Analysis.Journal of clinical medicine · 2024Review
- The Association Between Triglyceride-Glucose Index and Its Combination with Obesity Indicators and Lower Extremity Peripheral Artery Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Article
- Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study.Cardiovascular diabetology · 2023Article
- Association between fibrinogen level and length of stay in patients with lower extremity atherosclerotic disease: a retrospective cohort study.Scientific reports · 2023Article
- Peri-therapeutic multi-modal hemodynamic assessment and detection of predictors for symptomatic in-stent restenosis after percutaneous transluminal angioplasty and stenting.Frontiers in neurology · 2023Article
- Tissue factor targeting peptide enhances nanoparticle binding and delivery of a synthetic specialized pro-resolving lipid mediator to injured arteries.JVS-vascular science · 2023Article
- Bioadhesive Perivascular Microparticle-Gel Drug Delivery System for Intimal Hyperplasia Prevention: In Vitro Evaluation and Preliminary Biocompatibility Assessment.Gels (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease (PAD) of the lower extremities is a common manifestation of atherosclerosis that is increasing in global prevalence and in the associated public health costs. Ageing of the general population, combined with the pandemics of diabetes mellitus, metabolic syndrome, and tobacco use, is a major underlying factor. A broad range of care providers are involved in the management of patients with PAD, and all health-care professionals require familiarity with the risk factors, diagnosis, and treatment options for this common disease. Although medical therapies are the cornerstone of secondary prevention in atherosclerotic disease, they have limited direct limb-related benefits in advanced PAD. Despite a major evolution in technologies for limb revascularization, the increasing array of treatment options has not been accompanied by adequate evidence of their comparative effectiveness, which is needed to guide treatment decisions. This Review provides a framework for examining the current status of interventions for PAD, including an overview of disease staging, treatment goals, and the key factors associated with outcomes in defined subgroups. The status of evolving approaches to PAD, such as cell-based and gene-based therapies, and persistent unmet therapeutic needs in this field are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.